Gene · 10038
Papers2,674
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,674
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Design, Synthesis, and Pharmacodynamic Evaluation of Highly Selective PARP1 Inhibitors with Brain Penetrance. | J Med Chem | 2025 | 39789975 | PubTator, text mining | PubMed |
| Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer. | Future Oncol | 2025 | 39711161 | PubTator, text mining | PubMed |
| Insights into Cancer Cell Imaging Probes Based on Chalcone Scaffolds: Theoretical and Experimental Perspectives. | J Fluoresc | 2025 | 39693012 | PubTator, text mining | PubMed |
| Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer. | Future Med Chem | 2025 | 39691063 | PubTator, text mining | PubMed |
| Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents. | Neoplasia | 2025 | 39615107 | PubTator, text mining | PubMed |
| Olaparib: A Chemosensitizer for the Treatment of Glioblastoma. | Mini Rev Med Chem | 2025 | 39444180 | PubTator, text mining | PubMed |
| The Discovery of a Potent PARP1 Inhibitor Senaparib. | Mol Cancer Ther | 2025 | 38920409 | PubTator, text mining | PubMed |
| Evaluation of the efficacy of marine natural products against PARP-1/2 proteins in high-grade serous ovarian cancer: insights into MD and SMD simulations. | J Biomol Struct Dyn | 2025 | 38887043 | PubTator, text mining | PubMed |
| Evaluating the Anticancer Properties of Novel Piscidinol A Derivatives: Insights from DFT, Molecular Docking, and Molecular Dynamics Studies. | ACS Omega | 2024 | 39713673 | PubTator, text mining | PubMed |
| Aminomethylmorpholino Nucleosides as Novel Inhibitors of PARP1 and PARP2: Experimental and Molecular Modeling Analyses of Their Selectivity and Mechanism of Action. | Int J Mol Sci | 2024 | 39684238 | PubTator, text mining | PubMed |
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma. | Front Oncol | 2024 | 39640282 | PubTator, text mining | PubMed |
| PARP enzyme de novo synthesis of protein-free poly(ADP-ribose). | Mol Cell | 2024 | 39536748 | PubTator, text mining | PubMed |
| Targeted protein degradation: advances in drug discovery and clinical practice. | Signal Transduct Target Ther | 2024 | 39500878 | PubTator, text mining | PubMed |
| Synergy trap for guardian angels of DNA: Unraveling the anticancer potential of phthalazinone-thiosemicarbazone hybrids through dual PARP-1 and TOPO-I inhibition. | Bioorg Chem | 2024 | 39488147 | PubTator, text mining | PubMed |
| A Novel Prognostic Model of Hepatocellular Carcinoma per Two NAD+ Metabolic Synthesis-Associated Genes. | Int J Mol Sci | 2024 | 39408693 | PubTator, text mining | PubMed |
| Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts. | Mol Cell | 2024 | 39383878 | PubTator, text mining | PubMed |
| Synthesis and In Silico Evaluation of Piperazine-Substituted 2,3-Dichloro-5,8-dihydroxy-1,4-naphthoquinone Derivatives as Potential PARP-1 Inhibitors. | ACS Omega | 2024 | 39346823 | PubTator, text mining | PubMed |
| A comprehensive review of PRAME and BAP1 in melanoma: Genomic instability and immunotherapy targets. | Cell Signal | 2024 | 39326690 | PubTator, text mining | PubMed |
| The Rate of NAD+ Breakdown Is Maintained Constant against Deletion or Overexpression of NAD+-Degrading Enzymes in Mammalian Cells. | J Nutr Sci Vitaminol (Tokyo) | 2024 | 39218690 | PubTator, text mining | PubMed |
| DNA damage induced PARP-1 overactivation confers paclitaxel-induced neuropathic pain by regulating mitochondrial oxidative metabolism. | CNS Neurosci Ther | 2024 | 39215404 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10038/papers?page=7